KARYOPHARM THERAPEUTICS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.115 USD | -2.19% |
|
+2.29% | +28.90% |
| May. 08 | Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Reports Q1 Revenue $33.1M, vs. Street Est of $34.5M | MT |
| May. 08 | Transcript : Karyopharm Therapeutics Inc., Q1 2024 Earnings Call, May 08, 2024 |
Presentation Operator MessageOperator (Operator)Good morning. My name is Ayela, and I'll be yo...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Companyâs product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.
Calendar
2024-05-29
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.14
USD
Average target price
5.214
USD
Spread / Average Target
+357.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +28.90% | 134M | |
| +7.94% | 115B | |
| +12.96% | 107B | |
| -12.94% | 22.31B | |
| -3.99% | 21.6B | |
| -6.50% | 18.23B | |
| -39.93% | 17.62B | |
| +7.00% | 14.26B | |
| +32.56% | 12.37B | |
| -28.40% | 8.28B |
- Stock Market
- Equities
- KPTI Stock
- News Karyopharm Therapeutics Inc.
- Transcript : Karyopharm Therapeutics Inc. - Special Call